Esphera SynBio is developing next-generation cancer and immunoregulatory treatments through its innovative synthetic biology platform. The company develops advanced nanomedicines in the form of functionalized vesicles, which can be produced either in vitro or in vivo through their proprietary transgene technology. Esphera’s lead clinical candidate represents a novel approach in cancer immunotherapy - an off-the-shelf treatment that triggers tumor cells to generate a bespoke personalized cancer vaccine in vivo. Beyond oncology, Esphera's versatile platform shows promise in broader immunomodulation applications. 

Biotechnology

Esphera SynBio Inc

Org chart

Teams

Offices

Similar companies